Why Is Hims & Hers Health (HIMS) Stock Down -15% Today?
Key Takeaways
- HIMS shares are down approximately 15.15% in premarket trading on Tuesday, May 12, 2026, falling from Monday's closing price of $29.14 to around $24.73
- The primary catalyst is a significant Q1 2026 earnings miss: the company reported an EPS loss of -$0.40, compared to the analyst consensus estimate of +$0.04 — swinging from a profit of $0.20 per share in Q1 2025
- Revenue of $608.1 million came in below the consensus estimate of $616.84 million, and gross margin contracted sharply to 65% from 73% a year ago
- Q2 2026 EBITDA guidance of $35 million to $55 million fell below analyst expectations, which Citi characterized as "mixed"
- Full-year 2026 revenue guidance was lifted to a midpoint of $2.9 billion — up from $2.8 billion — but the raised top-line outlook was not enough to offset the margin disappointment
- Traders will focus on gross margin recovery, GLP-1 portfolio transition updates, and progress on the Eucalyptus acquisition in the quarters ahead
Opening Summary
Hims & Hers Health (HIMS) is a San Francisco-based telehealth and consumer health platform offering personalized treatments across categories including sexual health, hair loss, mental health, and weight management — most notably through GLP-1 weight-loss medications. Shares plunged approximately 15.15% in premarket trading on Tuesday, May 12, 2026, falling to around $24.73 from Monday's closing price of $29.14. The earnings-driven move followed the company's Q1 2026 results released after the close on May 11, which revealed a surprise net loss and a sharp contraction in profitability that blindsided Wall Street.
Q1 2026 Earnings Miss
The central driver of the selloff is an earnings result that dramatically reversed the company's recent profitability trajectory. HIMS reported an EPS loss of -$0.40 for Q1 2026, missing the consensus estimate of +$0.04 by more than 1,100% and reversing from a +$0.20 profit per diluted share in Q1 2025. The swing to a net loss of $92.1 million — compared to net income of $49.5 million in the year-ago quarter — underscored the weight of rising costs associated with the company's aggressive GLP-1 business buildout and its pending $1.15 billion acquisition of Australian digital health company Eucalyptus.
Gross Margin Compression
Beyond the headline EPS miss, the collapse in gross margin drew particular investor concern. Gross margin fell to 65% in Q1 2026, down from 73% in Q1 2025 — a deterioration of 8 percentage points in a single year that reflects rising costs tied to compounded GLP-1 medication fulfillment, regulatory compliance adjustments, and the shift toward lower-margin personalized weight-loss products. Adjusted EBITDA came in at $44.3 million, less than half the $91.1 million posted in Q1 2025, signaling that the company's operating leverage is moving in the wrong direction even as revenue grows.
Weak Q2 Guidance
Compounding the earnings miss, HIMS issued Q2 2026 guidance for Adjusted EBITDA of $35 million to $55 million — a range that analysts at Citi described as "mixed" and below their expectations. Revenue guidance for Q2 was set between $680 million and $700 million, which showed sequential improvement but failed to offset concerns about the profitability trajectory. While the company raised full-year 2026 revenue guidance to a midpoint of $2.9 billion (from the prior $2.8 billion midpoint) and maintained full-year Adjusted EBITDA guidance of $275 million to $350 million, the downward EBITDA revision versus prior expectations overshadowed the top-line lift.
Regulatory Backdrop: GLP-1 Headwinds
The earnings disappointment arrives against a challenging regulatory backdrop for HIMS in its highest-growth segment. The FDA has intensified scrutiny of compounded semaglutide products, resulting in a $65 million adverse impact to Q1 2026 performance as the company restructured how it ships personalized weight medications under U.S. prescription regulations. In March 2026, HIMS reached a deal with Novo Nordisk to sell branded Wegovy directly on its platform — a strategic pivot that carries lower margins than the compounded semaglutide products it had previously offered. This structural shift explains much of the margin pressure and is expected to continue weighing on near-term profitability.
Market Context and Trading Activity
Premarket volume for HIMS surged well above average, consistent with a high-conviction post-earnings selloff. Monday's regular session had already seen elevated activity — volume of approximately 58.6 million shares versus a 65-day average of roughly 21.39 million — as investors positioned ahead of the earnings print, and after-hours selling continued into Tuesday morning. The broader healthcare and telehealth sector was not experiencing comparable weakness, confirming the move is company-specific rather than macro-driven. Technically, HIMS had been recovering from a year-to-date pullback, trading in the upper $20s, and Tuesday's gap lower threatens to erase weeks of recovery progress and retest the stock's 2026 lows near the $25 range.
Trending AI Robots
For traders navigating earnings-driven volatility in names like HIMS, Tickeron's Trending AI Robots page highlights the platform's strongest-performing AI trading bots under current market conditions. Tickeron operates hundreds of AI bots spanning thousands of tickers, but only the top performers — ranked by live results — appear in this curated trending section. Each bot varies by strategy (momentum, swing, mean-reversion), timeframe, traded symbols, and risk/return metrics, allowing traders to match their approach to a bot that fits their style. Whether you are responding to a single-stock catalyst or managing a diversified portfolio through uncertain market conditions, exploring the Trending AI Robots lineup offers a data-driven starting point for systematic decision-making.
What Comes Next for HIMS
The next scheduled earnings report for HIMS is currently expected on August 3, 2026, when the company will report Q2 2026 results — the first quarter in which analysts will measure whether management's guidance proves achievable and whether margins have stabilized. Key near-term variables include the execution of the Eucalyptus acquisition, which is pending regulatory approval and represents a significant international expansion into digital health. Analysts will also be closely monitoring gross margin trends as the company fully transitions its GLP-1 business away from compounded semaglutide toward the branded Wegovy partnership with Novo Nordisk. The company's ability to sustain subscriber growth — which reached nearly 2.6 million in Q1 2026, up 9% year-over-year — will be another gauge of underlying demand health. Regulatory developments around compounded medications remain a persistent risk factor for HIMS and the broader telehealth sector.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
HIMS's Stochastic Oscillator is sitting in oversold zone for 2 days
Be on the lookout for a price bounce soon.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where HIMS advanced for three days, in of 278 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 264 cases where HIMS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The 10-day RSI Indicator for HIMS moved out of overbought territory on July 07, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 37 similar instances where the indicator moved out of overbought territory. In of the 37 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Momentum Indicator moved below the 0 level on July 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on HIMS as a result. In of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for HIMS turned negative on July 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HIMS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
HIMS broke above its upper Bollinger Band on June 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. HIMS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HIMS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock better than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (16.978) is normal, around the industry mean (46.654). P/E Ratio (57.137) is within average values for comparable stocks, (99.739). Projected Growth (PEG Ratio) (2.155) is also within normal values, averaging (1.668). HIMS has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.035). P/S Ratio (3.504) is also within normal values, averaging (114.968).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company, which is involved in real estate investment trusts
Industry PharmaceuticalsGeneric
Advertisement